Coordinated Financial Services Inc. Takes Position in Stryker Corporation $SYK

Key Points

• Coordinated Financial Services Inc. recently acquired 1,898 shares of Stryker Corporation, valued at approximately $751,000, as part of its investment strategy during the second quarter.
• Stryker Corporation is experiencing positive analyst sentiment, with fifteen analysts rating it as a "Buy" and a consensus price target of $430.10.
• The company's recent quarterly earnings report showed earnings of $3.13 per share, surpassing analysts' expectations, and an 11.1% year-over-year revenue increase to $6.02 billion.

Coordinated Financial Services Inc. purchased a new stake in Stryker Corporation (NYSE:SYK - Free Report) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 1,898 shares of the medical technology company's stock, valued at approximately $751,000.

A number of other large investors have also recently bought and sold shares of the stock. Moseley Investment Management Inc. bought a new stake in Stryker in the second quarter valued at $227,000. KRS Capital Management LLC bought a new stake in Stryker in the second quarter valued at $207,000. Horizon Bancorp Inc. IN bought a new stake in Stryker in the second quarter valued at $356,000. IFP Advisors Inc grew its position in Stryker by 1.2% in the second quarter. IFP Advisors Inc now owns 2,657 shares of the medical technology company's stock valued at $1,051,000 after acquiring an additional 31 shares during the period. Finally, Callan Family Office LLC grew its position in Stryker by 112.5% in the second quarter. Callan Family Office LLC now owns 8,792 shares of the medical technology company's stock valued at $3,478,000 after acquiring an additional 4,655 shares during the period. 77.09% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on SYK shares. Needham & Company LLC upped their price target on Stryker from $442.00 to $448.00 and gave the company a "buy" rating in a research report on Friday, August 1st. Rothschild Redb upgraded Stryker to a "hold" rating in a research report on Thursday, September 18th. Evercore ISI lowered their price target on Stryker from $418.00 to $410.00 and set an "outperform" rating on the stock in a research report on Tuesday. Weiss Ratings reissued a "buy (b-)" rating on shares of Stryker in a research note on Wednesday. Finally, Redburn Partners set a $420.00 price objective on Stryker in a research note on Thursday, September 18th. Fifteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Stryker currently has an average rating of "Moderate Buy" and a consensus price target of $430.10.

Stryker Price Performance

Stryker stock opened at $370.21 on Friday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. Stryker Corporation has a 52 week low of $329.16 and a 52 week high of $406.19. The firm has a market cap of $141.53 billion, a P/E ratio of 49.03, a P/E/G ratio of 2.70 and a beta of 0.94. The business's fifty day moving average is $380.53 and its two-hundred day moving average is $378.80.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business had revenue of $6.02 billion for the quarter, compared to analyst estimates of $5.92 billion. During the same quarter in the prior year, the firm posted $2.81 earnings per share. The firm's revenue for the quarter was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Equities research analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Stryker's dividend payout ratio is 44.50%.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of the company's stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the transaction, the director owned 3,222,108 shares of the company's stock, valued at $1,212,962,556.60. This represents a 5.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Viju Menon sold 500 shares of the company's stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the sale, the insider owned 12,511 shares of the company's stock, valued at $4,886,921.71. This represents a 3.84% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company's stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.